In May, Gilead Sciences secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its remdesivir to treat of hospitalised Covid-19 patients. Remdesivir is
Adult patients with relapsed or refractory FL whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two
The phase III IMpassion031 study assessing Tecentriq plus chemotherapy (Abraxane, albumin-bound paclitaxel, nab-paclitaxel, followed by doxorubicin and cyclophosphamide) comparison to placebo plus chemotherapy reached its primary endpoint by
These single-use culture containers are designed by Saint-Gobain to provide a closed systems approach to cell culture and cell manufacturing, allowing for a seamless translation of bioprocesses from
The approval is said to confirm the Cosentyx efficacy in the treatment of axial spondyloarthritis (axSpA) disease spectrus. Cosentyx is claimed to be the first and only fully-human
Under the strategic collaboration, the companies will develop and commercialise compounds in Takeda’s early-to-mid-stage psychiatry pipeline. As part of the deal, Neurocrine has secured an exclusive licence for
The study met the primary endpoint of non-inferiority on major adverse CV events (MACE), which is composed of a composite of CV death, nonfatal myocardial infarction or nonfatal
PML is a rare, aggressive, opportunistic brain infection caused by the reactivation of John Cunningham virus (JCV) in immunocompromised individuals. “The greatest barrier between PML patients and recovery
The phase 3 randomised, double-blind and placebo-controlled study will assess the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licenced from Incyte, in hospitalised adults with Covid-19.
Takeda will receive $266m upfront in cash and up to an additional $12 million USD in potential milestone payments, subject to customary legal and regulatory closing conditions. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.